Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests

References

• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205.
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Landewé R, Avouac J, EUSTAR Co-Authors, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–628.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Solomon DH, American G, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guideline. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49(3):399–412.
   PubMedGoogle Scholar
• Moinzadeh P, Nihtyanova SI, Howell K, et al. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012; 43(3) :249–255.
   PubMed Web of Science ®Google Scholar
• Cabral-Marques O, Riemekasten G. Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat Rev Rheumatol. 2017;13(11):648–656.
   PubMed Web of Science ®Google Scholar
• Affandi AJ, Radstake TR, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol. 2015;37(5):475–487.
   PubMed Web of Science ®Google Scholar
• Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15(1):102–109.
   PubMed Web of Science ®Google Scholar
• Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol. 2014;26(6):646–652.
   PubMed Web of Science ®Google Scholar
• Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13(5):R172.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755.
   PubMed Web of Science ®Google Scholar
• Bonroy C, Van Praet J, Smith V, et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods. 2012;379(1–2):53–60.
   PubMed Web of Science ®Google Scholar
• van den Hombergh WMT, Carreira PE, Knaapen-Hans HKA, et al. An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. Rheumatology. 2016;55(11):2023–2032.
   PubMed Web of Science ®Google Scholar
• Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747.
   PubMed Web of Science ®Google Scholar
• Villalta D, Imbastaro T, Di Giovanni S, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev. 2012;12(2):114–120.
   PubMed Web of Science ®Google Scholar
• Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–889.
   PubMed Web of Science ®Google Scholar
• Patterson KA, Roberts-Thomson PJ, Lester S, et al. Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol. 2015;67(12):3234–3244.
   PubMed Web of Science ®Google Scholar
• Liaskos C, Marou E, Simopoulou T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 2017;50(7):414–421.
   PubMed Web of Science ®Google Scholar
• Meyer OC, et al. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34(1):104–109.
   PubMed Web of Science ®Google Scholar
• Mejia Otero C, Assassi S, Hudson M, Genetics versus Environment in Scleroderma Outcome Study, et al. Antifibrillarin antibodies are associated with native North American ethnicity and poorer survival in systemic sclerosis. J Rheumatol. 2017;44(6):799–805.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, et al. Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity. 2011;44(7):576–584.
   PubMed Web of Science ®Google Scholar
• Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am. 2008;34(1):1–15.
   PubMed Web of Science ®Google Scholar
• Plebani M. Harmonization in laboratory medicine: more than clinical chemistry? Clin Chem Lab Med. 2018;56(10):1579–1586.
   PubMed Web of Science ®Google Scholar
• Moinzadeh P, Fonseca C, Hellmich M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther. 2014;16(1):R53.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kodera M, Matsushita T, et al. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol. 2015;67(4):1045–1052.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Bérezné A, Bussone G, et al. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):84–91.
   PubMed Web of Science ®Google Scholar
• Lazzaroni M-G, Cavazzana I, Colombo E, EUSTAR co-authors, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol. 2017;44(5):639–647.
   PubMed Web of Science ®Google Scholar